January 2002
Royal Society of Medicine: Medicines;2002, p206
Reference Entry
This article presents information on the drug Diovan, a proprietary, prescription-only preparation of the angiotensin-receptor blocker valsartan. It can be used as an antihypertensive, and is available in capsules.


Related Articles

  • Angiotensin blockade by saralasin bolus injection. Maxwell, Morion H.; Marks, Leonard S. // Kidney International Supplement;Mar1979, Issue 9, p53 

    Discusses the method of saralasin bolus test (SBT). Discontinuation of all antihypertensive and diuretic medication in advance of the test to allow complete clearance from the body; Interpretation of SBT; SBT versus preinjection level determination.

  • Angiotensin-(1–7) stimulates water transport in rat inner medullary collecting duct: evidence for involvement of vasopressin V2 receptors. Magaldi, A. J.; Cesar, K. R.; e Araújo, M.; e Silva, A. C. Simões; Santos, R. A. S. // Pflugers Archiv European Journal of Physiology;Nov2003, Vol. 447 Issue 2, p223 

    The peptide angiotensin-(1–7) [Ang-(1–7)] is known to enhance water transport in rat inner medullary collecting duct (IMCD). The aim of this study was to determine the mechanism of the Ang-(1–7) effect on osmotic water permeability (Pf). Pf was measured in the normal rat...

  • Angiotensin II blockade by saralasin in the evaluation of hypertension in children. Favre, Laurent; Boerth, Robert C.; Braren, Victor; Dean, Richard H.; Hollifield, John W. // Kidney International Supplement;Mar1979, Issue 9, p75 

    Twenty-nine children, aged 4 to 18 years, with sustained hypertension (admission BP. 158 ± 5/107 ± 4 mm Hg. mean ± SEM) received saralasin ([Sar, Ala]-AII), a competitive antagonist of All, during their diagnostic evaluation. According to the findings of renal or aortic arteriography,...

  • Comparison between saralasin and converting enzyme inhibitor in hypertensive disease. Case, David B.; Wallace, John M.; Laragh, John H. // Kidney International Supplement;Mar1979, Issue 9, p107 

    Comparison between saralasin and converting enzyme inhibitor in hypertensive disease. The effects of either saralasin or converting enzyme inhibitor SQ20881 were studied in seated, unmedicated hypertensive patients. Both drugs lowered BP in high-renin patients, and did so equally well in...

  • Historical development of saralasin. Pals, Donald T.; Denning Jr., George S.; Keenan, Robert E. // Kidney International Supplement;Mar1979, Issue 9, p7 

    The research environment in which saralasin was discovered has been described, and illustrations of the rationale which contributed to its synthesis, selection for development, and eventual development have been presented. As an example, the synthesis of [Sar, Val, Ala]-AII (P113, saralasin) was...

  • Hemodynamic correlates of saralasin: Responsiveness in hypertension. Kem, David C.; Frohlich, Edward D.; de Carvalho, Jose G. R.; Dunn, Francis G.; Chrysant, Steven G.; Danisa, Kola; Wambach, Gerhard // Kidney International Supplement;Mar1979, Issue 9, p68 

    We have measured systemic hemodynamics before, during and after the infusion of saralasin in 28 hypertensive patients to determine its cardiovascular effects. The patients were divided into responders. nonresponders or pressor-responders on the basis of a 10-mm-Hg change in MAP. Of the nine...

  • Angiotensin-receptor blocker (Major drug group).  // Royal Society of Medicine: Medicines;2002, p62 

    The article presents information on angiotensin-receptor blocker drugs. The drugs work by blocking angiotensin receptors. Recently introduced drugs of this type include: candesartan, cilexetil, eprosartan, irbesartan, losartan, potassium, telmisartan and valsartan, which can be used as...

  • Drug interactions with saralasin. Mitchell, Helen C.; Keeton, T. Kent; Pettinger, William A. // Kidney International Supplement;Mar1979, Issue 9, p101 

    Diuretic and vasodilator drugs alter the BP response to saralasin causing drug interactions. Saralasin-induced BP reduction is related directly to PRA and intravascular volume. Diuretic agents deplete intravascular volume and elevate PRA, enhancing saralasin hypotension. Vasodilating agents...

  • Teveten.  // Royal Society of Medicine: Medicines;2002, p531 

    This article presents information on Teveten, a a proprietary, prescription-only preparation of the angiotensin-receptor blocker eprosartan. It can be used as an antihypertensive, and is available as tablets.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics